105 related articles for article (PubMed ID: 16872824)
1. Multilocus loss of heterozygosity allelotypes identify a genetic pathway associated with progression from low to high stage disease in neuroblastoma.
Chughtai SA; Genus T; Ramani P; Dyer S; Powell JE; McMullan D; Davison V; McConville CM;
Eur J Cancer; 2006 Aug; 42(12):1826-34. PubMed ID: 16872824
[TBL] [Abstract][Full Text] [Related]
2. Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease.
Mora J; Cheung NK; Chen L; Qin J; Gerald W
Cancer; 2001 Jan; 91(2):435-42. PubMed ID: 11180092
[TBL] [Abstract][Full Text] [Related]
3. Loss of heterozygosity for chromosome 14q in neuroblastoma.
Thompson PM; Seifried BA; Kyemba SK; Jensen SJ; Guo C; Maris JM; Brodeur GM; Stram DO; Seeger RC; Gerbing R; Matthay KK; Matise TC; White PS
Med Pediatr Oncol; 2001 Jan; 36(1):28-31. PubMed ID: 11464899
[TBL] [Abstract][Full Text] [Related]
4. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas.
Guo C; White PS; Weiss MJ; Hogarty MD; Thompson PM; Stram DO; Gerbing R; Matthay KK; Seeger RC; Brodeur GM; Maris JM
Oncogene; 1999 Sep; 18(35):4948-57. PubMed ID: 10490829
[TBL] [Abstract][Full Text] [Related]
5. Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma.
Maris JM; Guo C; White PS; Hogarty MD; Thompson PM; Stram DO; Gerbing R; Matthay KK; Seeger RC; Brodeur GM
Med Pediatr Oncol; 2001 Jan; 36(1):24-7. PubMed ID: 11464895
[TBL] [Abstract][Full Text] [Related]
6. Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas.
Ambros PF; Ambros IM; Kerbl R; Luegmayr A; Rumpler S; Ladenstein R; Amann G; Kovar H; Horcher E; De Bernardi B; Michon J; Gadner H
Med Pediatr Oncol; 2001 Jan; 36(1):1-4. PubMed ID: 11464855
[TBL] [Abstract][Full Text] [Related]
7. Numerical and structural aberrations in advanced neuroblastoma tumours by CGH analysis; survival correlates with chromosome 17 status.
Cunsolo CL; Bicocchi MP; Petti AR; Tonini GP
Br J Cancer; 2000 Nov; 83(10):1295-300. PubMed ID: 11044353
[TBL] [Abstract][Full Text] [Related]
8. Chromosome 14q LOH in localized clear cell renal cell carcinoma.
Mitsumori K; Kittleson JM; Itoh N; Delahunt B; Heathcott RW; Stewart JH; McCredie MR; Reeve AE
J Pathol; 2002 Sep; 198(1):110-4. PubMed ID: 12210070
[TBL] [Abstract][Full Text] [Related]
9. Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis.
Luttikhuis ME; Powell JE; Rees SA; Genus T; Chughtai S; Ramani P; Mann JR; McConville CM
Br J Cancer; 2001 Aug; 85(4):531-7. PubMed ID: 11506492
[TBL] [Abstract][Full Text] [Related]
10. Genetic alterations involving chromosome 1p in children with neuroblastoma.
Avigad S; Tamir Y; Yaniv I; Goshen J; Kaplinsky C; Cohen IJ; Zaizov R
Isr J Med Sci; 1994 Aug; 30(8):639-41. PubMed ID: 7913920
[TBL] [Abstract][Full Text] [Related]
11. Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q.
Fischer M; Bauer T; Oberthür A; Hero B; Theissen J; Ehrich M; Spitz R; Eils R; Westermann F; Brors B; König R; Berthold F
Oncogene; 2010 Feb; 29(6):865-75. PubMed ID: 19901960
[TBL] [Abstract][Full Text] [Related]
12. Loss of heterozygosity in neuroblastomas--an overview.
Takita J; Hayashi Y; Yokota J
Eur J Cancer; 1997 Oct; 33(12):1971-3. PubMed ID: 9516835
[TBL] [Abstract][Full Text] [Related]
13. Expression of the tumour suppressor gene CADM1 is associated with favourable outcome and inhibits cell survival in neuroblastoma.
Nowacki S; Skowron M; Oberthuer A; Fagin A; Voth H; Brors B; Westermann F; Eggert A; Hero B; Berthold F; Fischer M
Oncogene; 2008 May; 27(23):3329-38. PubMed ID: 18084322
[TBL] [Abstract][Full Text] [Related]
14. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.
Spitz R; Hero B; Skowron M; Ernestus K; Berthold F
Eur J Cancer; 2004 Dec; 40(18):2753-9. PubMed ID: 15571958
[TBL] [Abstract][Full Text] [Related]
15. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma.
Spitz R; Hero B; Simon T; Berthold F
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3368-73. PubMed ID: 16740759
[TBL] [Abstract][Full Text] [Related]
16. Analysis of neuroblastoma tumour progression; loss of PHOX2B on 4p13 and 17q gain are early events in neuroblastoma tumourigenesis.
Krona C; Carén H; Sjöberg RM; Sandstedt B; Laureys G; Kogner P; Martinsson T
Int J Oncol; 2008 Mar; 32(3):575-83. PubMed ID: 18292934
[TBL] [Abstract][Full Text] [Related]
17. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
Warnat P; Oberthuer A; Fischer M; Westermann F; Eils R; Brors B
BMC Cancer; 2007 May; 7():89. PubMed ID: 17531100
[TBL] [Abstract][Full Text] [Related]
18. Weak linkage at 4p16 to predisposition for human neuroblastoma.
Perri P; Longo L; Cusano R; McConville CM; Rees SA; Devoto M; Conte M; Ferrara GB; Seri M; Romeo G; Tonini GP
Oncogene; 2002 Nov; 21(54):8356-60. PubMed ID: 12447700
[TBL] [Abstract][Full Text] [Related]
19. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression.
Mosse YP; Diskin SJ; Wasserman N; Rinaldi K; Attiyeh EF; Cole K; Jagannathan J; Bhambhani K; Winter C; Maris JM
Genes Chromosomes Cancer; 2007 Oct; 46(10):936-49. PubMed ID: 17647283
[TBL] [Abstract][Full Text] [Related]
20. Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p.
Mora J; Cheung NK; Kushner BH; LaQuaglia MP; Kramer K; Fazzari M; Heller G; Chen L; Gerald WL
J Mol Diagn; 2000 Feb; 2(1):37-46. PubMed ID: 11272900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
